Did Universal Access to ARVT in Mexico Impact Suboptimal Antiretroviral Prescriptions?
- PMID: 24396592
- PMCID: PMC3874343
- DOI: 10.1155/2013/170417
Did Universal Access to ARVT in Mexico Impact Suboptimal Antiretroviral Prescriptions?
Abstract
Background. Universal access to antiretroviral therapy (ARVT) started in Mexico in 2001; no evaluation of the features of ARVT prescriptions over time has been conducted. The aim of the study is to document trends in the quality of ARVT-prescription before and after universal access. Methods. We describe ARVT prescriptions before and after 2001 in three health facilities from the following subsystems: the Mexican Social Security (IMSS), the Ministry of Health (SSA), and National Institutes of Health (INS). Combinations of drugs and reasons for change were classified according to current Mexican guidelines and state-of-the-art therapy. Comparisons were made using χ (2) tests. Results. Before 2001, 29% of patients starting ARVT received HAART; after 2001 it increased to 90%. The proportion of adequate prescriptions decreased within the two periods of study in all facilities (P value < 0.01). The INS and SSA were more likely to be prescribed adequately (P value < 0.01) compared to IMSS. The distribution of reasons for change was not significantly different during this time for all facilities (P value > 0.05). Conclusions. Universal ARVT access in Mexico was associated with changes in ARVT-prescription patterns over time. Health providers' performance improved, but not homogeneously. Training of personnel and guidelines updating is essential to improve prescription.
Figures



Similar articles
-
Improving physician prescribing patterns to treat rhinopharyngitis. Intervention strategies in two health systems of Mexico.Soc Sci Med. 1996 Apr;42(8):1185-94. doi: 10.1016/0277-9536(95)00398-3. Soc Sci Med. 1996. PMID: 8737437 Clinical Trial.
-
Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: lessons from Mexico.AIDS. 2006 Jan 2;20(1):101-9. doi: 10.1097/01.aids.0000198096.08444.53. AIDS. 2006. PMID: 16327325
-
[Antiretroviral therapy of HIV infection: duration and reasons for changing the first therapeutic regimen in 518 patients].Med Clin (Barc). 2006 Feb 25;126(7):241-5. doi: 10.1157/13085280. Med Clin (Barc). 2006. PMID: 16510064 Spanish.
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Fourth Wave of Opioid (Illicit Drug) Overdose Deaths and Diminishing Access to Prescription Opioids and Interventional Techniques: Cause and Effect.Pain Physician. 2022 Mar;25(2):97-124. Pain Physician. 2022. PMID: 35322965 Review.
Cited by
-
Survival benefits of antiretroviral therapy in Brazil: a model-based analysis.J Int AIDS Soc. 2016 Mar 29;19(1):20623. doi: 10.7448/IAS.19.1.20623. eCollection 2016. J Int AIDS Soc. 2016. PMID: 27029828 Free PMC article.
-
Psychological model of ART adherence behaviors in persons living with HIV/AIDS in Mexico: a structural equation analysis.Rev Saude Publica. 2017 Sep 4;51:81. doi: 10.11606/S1518-8787.2017051006926. Rev Saude Publica. 2017. PMID: 28876412 Free PMC article.
-
Engagement in the HIV Care Continuum among Key Populations in Tijuana, Mexico.AIDS Behav. 2016 May;20(5):1017-25. doi: 10.1007/s10461-015-1186-8. AIDS Behav. 2016. PMID: 26354518 Free PMC article.
References
-
- Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England Journal of Medicine. 1998;338(13):853–860. - PubMed
-
- WHO. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach. 2004. - PubMed
-
- Open Society Institute. Breaking down barriers: lessons on providing HIV treatment to injection drug users. IHRD Report. 2004
-
- Bautista-Arredondo S, Dmytraczenko T, Kombe G, Bertozzi SM. Costing of scaling up HIV/AIDS treatment in Mexico. Salud pública de México. 2008;50(supplement 4):S437–S444. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials